Format

Send to

Choose Destination
Oncology (Williston Park). 2013 Oct;27(10):1028, 1030.

The use of serum hCG as a marker of tumor progression and of the response of metastatic urothelial cancer to systemic chemotherapy.

Author information

1
Yale-New Haven Hospital, New Haven, Connecticut, USA.
2
Division of Oncology, Department of Medicine, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.
3
Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA.
4
Department of Urology, Yale School of Medicine, New Haven, Connecticut, USA.

Abstract

This case confirms the observation that urothelial carcinomas can secrete beta-hCG, and that beta-hCG can potentially be used as a marker of a patient's clinical response to treatment. Prospective studies are clearly warranted by these observations.

PMID:
24367863
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for UBM Medica LLC
Loading ...
Support Center